InkVivo Technologies AG’s Post

🌟 Ashibiotech Raises $40M in Seed and Series A Financing! 🚀 We're thrilled to announce that Ashibiotech, a leading innovator in the biotech industry, has successfully raised $40 million in Seed and Series A funding. This significant investment will fuel their mission to revolutionise healthcare with cutting-edge biotechnological solutions. 💡 Key Highlights: -Funding Details: The $40 million raised includes contributions from top-tier investors, demonstrating strong confidence in Ashibiotech's vision and potential. -Innovation Focus: Ashibiotech is committed to advancing healthcare with breakthrough technologies that promise to make a substantial impact on patient outcomes. -Growth and Expansion: This funding will accelerate R&D efforts, enhance product development, and support expansion into new markets. With this fresh capital, Ashibiotech is poised to drive innovation and bring transformative biotech solutions to the global healthcare landscape. 🌍 #Biotech #HealthcareInnovation #Funding #StartupSuccess #Ashibiotech #SeriesAFunding #SeedFunding #TechNews #Innovation #HealthcareRevolution

What's the latest advice for biotech startups to navigate the current market? Some tips from BioPharma Dive’s panel highlight the following: - Platform companies are gaining funding but there’s a greater focus on lead programs and the future commercial opportunity - Series A rounds need to be larger to gather sufficient data until there’s a major inflection point in the program - Achieve balance between capital efficiency and value creation by making very careful decisions about what to invest in - Reassess clinical hypotheses and pivot as information changes https://lnkd.in/en6YipD2: 2024-11-18 BioPharma Dive %5Bissue:67953%5D&utm_term=BioPharma Dive #VC #biotech #strategy

🚀 Exciting developments in the biotech sector! Atlas Venture has announced the launch of a substantial $450M fund, just two years after its previous one. This strategic move underscores Atlas's commitment to supporting innovative biotech startups. 🔬 With a focus on transformative technologies and breakthrough therapies, this fund aims to fuel advancements in biotechnology that could reshape patient care and medical treatments. The substantial investment reflects a robust confidence in the sector’s ability to deliver cutting-edge solutions in healthcare. 📊 According to the article on Fierce Biotech, this fund is targeted at the next wave of pioneering biotechs, emphasizing the critical need for continuous funding and backing for early-stage life science innovations. Let's watch how this new funding initiative catalyzes progress in the biotech realm! For more insights, read the full article here: https://lnkd.in/eN2cyYEc #Biotech #Innovation #AtlasVenture #Investment #Healthcare

There are just a couple more days left before BIO EUROPE SPRING starts and Citeline Commercial just published a really insightful article on InVivo. Biotechs have faced challenges in the last couple years on many aspects: achieving clinical and regulatory milestones, appeasing investors whom are less willing to take risks on early-stage assets, and a buyer’s market in favor of pharma dealmakers. Public markets have been difficult to reach in the last 12 months as well, and for venture capitalists, raising new funds has been a struggle. On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023. Looking forward to have some great discussions in Barcelona and please make sure you that you won't miss the panel discussions with our Director Thought Leadership at Citeline, Daniel Chancellor #citeline #invivo #funding #biotech #pharma #lifescience #bioeurope #bioeuropespring

SFBN Feed: Biotech VC firm outlines plans for $100M fund https://lnkd.in/gwEQJkbd An early-stage biotech investor called YK Bioventures plans to raise $100 million, according to an SEC filing on Wednesday. The VC firm has invested in at least five startups, according to public disclosures. That includes [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

🧡 🧡 🧡 ... #Crowdfunding in PIRCHE AG: I naturally seized the opportunity to invest in a #German champion of the #digital #healthcare #industry. ⬆️Nothing is without risk in life, but it also offers very good #opportunities ... investment opportunities for example. ⬇️ 👉 I have known Thomas Klein, the brain and founder behind PIRCHE, for many years; we first met at a DZ BANK AG investment forum in 2000, when I was still Managing Director at the daugher company of GoingPublic Media AG. 👉 After his career in #politics, Thomas dedicated himself to the #biotech sector more than 20 years ago, with the success of a serial entrepreneur; NOXXON Pharma N.V., ARCWAY AG ... 1️⃣ With PIRCHE, he is now well on the way to developing a #global player in the digital healthcare industry out of #Germany with a profound team of specialists, e.g. Bethany L. Dale, PhD, Matthias Niemann, etc. 2️⃣ The first #business area: #kidney #transplantation: half of all kidney transplants still fail in the first 5 to 10 years, resulting in the death of the patient, serious side effects or severe restrictions in a self-determined life. 3️⃣ PIRCHE has developped a solution with its #AI-supported #diagnostic #platform, which is already based on the experience and results of more than 250,000 patient cases in over 80 top #publications. 💪 What continues to convince me to be involved with an investment: 4️⃣ 25 #patent families with protection in #Europe, #USA and countries in #Asia 5️⃣ Top partners with ThermoFisher Scientific, Werfen and Immucor, Inc. 6️⃣ Well-known and serially successful #entrepreneurs and #investors in the #lifescience industry 💪 In the USA, seven-figure sales are already being made with top clinics 😉 The signs are good to get started in 2026 and roll out the technology globally --- not to mention the opportunities offered by the PIRCHE platform for #advanced therapies, including cell-based therapies. ❗️❗️❗️And not to forget: the increase in value, the #multiple that can be achieved with #investments before the #IPO, in the #preIPO stage. Follow Robin Binder's explanations https://lnkd.in/dM-6ukrc

We are so happy to share that we have received funding from BIO-X Accelerate💥. With the support from the call that focus 🎯in on IMPACT we will pursue our work on the Adaptable Drug Affinity Conjugate (ADAC) technology💊, to provide a technology for targeted delivery of oligonucleotide-based therapies! Together with our collaborators Jonas Nilsson Tommy Lidström Ulf Tedebark OLIGOMED - Oligonucleotides for Medical Applications and our investors we can ramp up our efforts 👊🎉 STUNS Life science European Regional Development Fund Tillvaxtverket Eir Ventures Flerie Uppsala universitet Invest AB Olle Wahlqvist Almi Invest SLU Holding AB https://lnkd.in/dgxZ2wKv About BIO-X BIO-X Accelerate is a program with the goal of accelerating the development of innovation in the health and/or life science industry. The program uses an industrial approach to support life science-related projects that could fulfill well-defined needs and create IMPACT in healthcare, industry and society. Selected companies receive funding for their projects as well as continued support and access to experts within the BIO-X network. BIO-X Accelerate with the theme IMPACT is a project by STUNS with strategic partners UIC, Connect Uppsala, Create Business Incubator, Lead (Business Incubator), Inkubera and supporting partners Linköping University Innovation, Uppsala University and Örebro University Holding. The project is financed by European Regional Development Fund (ERDF) through The Swedish Agency for Economic and Regional Growth via STUNS. About STUNS STUNS is the foundation for collaboration between the universities in Uppsala, business and society. STUNS Life science is a strategic hub for collaboration between private and public actors to contribute to sustainable knowledge-based growth - in life science, health and neighboring disciplines.

A great read from Nature Portfolio about co-working labs for #biotech #startups. The article explores how shared lab spaces enhance startup growth by fostering a sense of community, providing access to mentors and saving costs. STEMCELL Technologies #biotechinnovation #biotechrevolution #coworkinglabs #collaborativeresearch #labspace #startupcommunity #innovationinscience #startupsuccess

🎢 𝗕𝗲 𝗜𝗻𝘀𝗽𝗶𝗿𝗲𝗱 𝗯𝘆 𝗧𝗵𝗶𝗲𝗿𝗿𝘆 𝗠𝗮𝘂𝘃𝗲𝗿𝗻𝗮𝘆'𝘀 𝗘𝗻𝘁𝗿𝗲𝗽𝗿𝗲𝗻𝗲𝘂𝗿𝗶𝗮𝗹 𝗝𝗼𝘂𝗿𝗻𝗲𝘆! As the President of Debiopharm (in #Lausanne and #Martigny), Thierry Mauvernay exemplifies the spirit of #innovation and perseverance essential in the #biopharmaceutical industry. His unique approach, which combines long-term #vision and entrepreneurial #agility, was highlighted in his portrait, published this month on PME. 𝗔 𝗕𝘂𝘀𝗶𝗻𝗲𝘀𝘀 𝗠𝗼𝗱𝗲𝗹 𝗙𝗼𝗰𝘂𝘀𝗲𝗱 𝗼𝗻 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 Debiopharm stands out with its original business model : 📌 Emphasis on R&D and clinical phases 📌Strategic partnerships for commercialization 📌Targeted investments in promising startups This strategy maximizes impact while managing the inherent risks of our industry. 𝗔 𝗖𝗼𝗺𝗺𝗶𝘁𝗺𝗲𝗻𝘁 𝘁𝗼 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 Thierry Mauvernay emphasizes a crucial point: "𝘐𝘯 𝘱𝘩𝘢𝘳𝘮𝘢, 𝘭𝘦𝘴𝘴 𝘵𝘩𝘢𝘯 5% 𝘰𝘧 𝘙&𝘋 𝘱𝘳𝘰𝘫𝘦𝘤𝘵𝘴 𝘭𝘦𝘢𝘥 𝘵𝘰 𝘵𝘩𝘦 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭𝘪𝘻𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘢 𝘯𝘦𝘸 𝘮𝘰𝘭𝘦𝘤𝘶𝘭𝘦, 𝘢 𝘱𝘳𝘰𝘤𝘦𝘴𝘴 𝘵𝘩𝘢𝘵 𝘵𝘢𝘬𝘦𝘴 𝘣𝘦𝘵𝘸𝘦𝘦𝘯 15 𝘵𝘰 20 𝘺𝘦𝘢𝘳𝘴 𝘢𝘯𝘥 𝘤𝘰𝘴𝘵𝘴 𝘢𝘯 𝘢𝘷𝘦𝘳𝘢𝘨𝘦 𝘰𝘧 1 𝘣𝘪𝘭𝘭𝘪𝘰𝘯 𝘧𝘳𝘢𝘯𝘤𝘴." Despite these challenges, Debiopharm remains steadfast, guided by its mission to improve patients' lives. 🩺 𝗦𝘄𝗶𝘀𝘀 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗖𝗲𝗻𝘁𝗲𝗿: 𝗬𝗼𝘂𝗿 𝗣𝗮𝗿𝘁𝗻𝗲𝗿 𝗳𝗼𝗿 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 At Swiss Biotech Center, we share this vision. Our support services in R&D and #incubation are designed to empower bold #entrepreneurs in the life sciences sector. 🚀 ➡️ 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝘂𝘀 𝗻𝗼𝘄 : https://lnkd.in/dYXsie7Q 🙋🏻♀️🙋🏻♂️ Together, let’s tackle tomorrow's challenges and shape the future of healthcare! 👀 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗠𝗮𝘂𝘃𝗲𝗿𝗻𝗮𝘆'𝘀 𝗳𝘂𝗹𝗹 𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝗶𝗻 PME : https://lnkd.in/dr8PU5vU #Innovation #Biotech #Entrepreneurship #ResearchAndDevelopment #LifeSciences #Startups #Universities #Projects #Business #Opportunities #EarlyStage #Partnerships #SmallBatch #Facilities #Coaching #FinancialSupport BioAlps - Life Sciences Cluster 🇨🇭 BioArk Swiss Biotech Association Promotion économique Valais

Money is flowing back into biopharma. InnovationRx reports that venture investments in biopharma and medtech have reversed a two-year slide, signaling renewed confidence and growth in these critical sectors. There is no doubt 2024 was a downturn year with headwinds in healthcare. The future in 2025 is looking optimistic. This resurgence not only highlights the ongoing demand for innovative solutions in medicine and technology but also reflects the vital role that investment plays in driving breakthroughs. As funding flows back into biopharma and medtech, we can expect to see advancements that improve patient outcomes and reshape the healthcare landscape. We need to continue to celebrate this momentum and support innovation that can change lives. #InnovationRx #Biopharma #Medtech #HealthcareInnovation #InvestmentTrends